Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis-Reference-Cited by-同舟云学术

Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis

Published:2021-10-10 Issue:1 Volume:89 Page:11-20
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Mukozu Takanori^ORCID,Nagai Hidenari,Matsui Daigo,Mohri Kunihide,Watanabe Go,Yoshimine Naoyuki,Amanuma Makoto,Kobayashi Kojiro,Ogino Yu,Matsukiyo Yasushi,Matsui Teppei,Daido Yasuko,Wakui Noritaka,Shinohara Mie,Momiyama Koichi,Higai Koji,Igarashi Yoshinori

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04359-2.pdf

Reference39 articles.

1. Tohyama O, Matsui J, Kodama K et al (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747

2. Matsuki M, Hoshi T, Yamamoto Y et al (2018) Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 7(6):2641–2653

3. Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173

4. Kudo M (2018) Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma. Liver Cancer 7(3):215–224

5. Kudo M (2018) Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer 7(1):1–19

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world drug safety surveillance study of lenvatinib from the FAERS database;Expert Opinion on Drug Safety;2024-08-21

2. Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis;ImmunoTargets and Therapy;2024-06

3. Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis;Journal of Liver Cancer;2024-03-31

4. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-20

5. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study;Journal of Hepatocellular Carcinoma;2023-10